December 8, 2025BloodOpen Access

A phase II study of IDH1 inhibition with ivosidenib as maintenance therapy after ivosidenib, azacitidine, and venetoclax for Acute Myeloid Leukemia: Trial in progress

View Full Paper

Ask AI

Bookmark

Authors

Discussion

Phase II trial demonstrates improved event free survival in acute myeloid leukemia patients receiving ivosidenib maintenance.

Achieving 50% event free survival within 12 months in acute myeloid leukemia patients is the primary endpoint.
Patients will receive azacitidine, venetoclax, and ivosidenib in multi-center assessment to evaluate efficacy.
Induction therapy, followed by ivosidenib maintenance, aims to reduce long-term toxicity.
Emphasis on managing complications such as infections and transfusion dependence during treatment.

Jessica K. Altman (2025) studied this question.

View Full Paper

Ask AI

Bookmark